James F. Borin

James F. Borin

Auto-generated profile, based on publicly available information

James F. Borin

Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RHRobert S. Hudson
Robert S. Hudson
MYMing Yi
Ming Yi
DEDominic Esposito
Dominic Esposito
SWStephanie K. Watkins
Stephanie K. Watkins
AHArthur A. Hurwitz
Arthur A. Hurwitz
Stefan AmbsStefan Ambs
Stefan Ambs
We previously reported that miR-1 is among the most consistently down-regulated miRs in primary human prostate tumors. In this follow-up study, we further corroborated this finding in an independent data set and made the novel observation that miR-1 expression is further reduced in distant metastasis and is a candidate predictor of disease recurrence. Moreover, we performed in vitro experiments to explore the tumor suppressor function of miR-1. Cell-based assays showed that miR-1 is epigenetically silenced in human prostate cancer. Overexpression of miR-1 in these cells led to growth inhibition and down-regulation of genes in pathways regulating cell cycle progression, mitosis, DNA replication/repair and actin dynamics. This observation was further corroborated with protein expression analysis and 3′-UTR-based reporter assays, indicating that genes in these pathways are either direct or indirect targets of miR-1. A gene set enrichment analysis revealed that the miR-1-mediated tumor suppressor effects are globally similar to those of histone deacetylase inhibitors. Lastly, we obtained preliminary evidence that miR-1 alters the cellular organization of F-actin and inhibits tumor cell invasion and filipodia formation. In conclusion, our findings indicate that miR-1 acts as a tumor suppressor in prostate cancer by influencing multiple cancer-related processes and by inhibiting cell proliferation and motility.

1 May 2008 in Journal of Endourology
Verified
Journal Article
Closed access
LDLeslie A. Deane
Leslie A. Deane
HLHak J. Lee
Hak J. Lee
GBGeoffrey N. Box
Geoffrey N. Box
OMOri Melamud
Ori Melamud
DYDavid S. Yee
David S. Yee
DODavid K. Ornstein
David K. Ornstein
Purpose: Laparoscopic partial/wedge nephrectomy, similar to laparoscopic radical prostatectomy, is a technically challenging procedure that is performed by a limited number of expert laparoscopic surgeons. The incorporation of a robotic surgical interface has dramatically increased the use of minimally invasive pelvic surgery such that robotic laparoscopic radical prostatectomy is commonly performed even by laparoscopically naïve surgeons. This analysis compares the outcomes of our initial experience with robot-assisted laparoscopic partial nephrectomy (RLPN) performed by an experienced open surgeon to that of standard laparoscopic partial nephrectomy (LPN) performed by two experienced laparoscopic surgeons. Patients and Methods: We reviewed the medical records of 11 consecutive patients who underwent 12 standard LPNs (EMM, RVC) (one patient had two unilateral tumors) and 10 consecutive patients (representing the first 11 of such robotic procedures performed at our institution) who underwent 11 RLPNs (one patient had bilateral tumors managed in an asynchronous manner) (DKO). Results: The mean tumor size was 2.3 cm (range 1.7–6.2 cm) for LPN and 3.1 cm (range 2.5–4 cm) for RLPN. The mean total procedure time was 289.5 minutes (range 145–369 min) for LPN and 228.7 minutes (range 98–375 min) for RLPN (P = 0.102). The mean estimated blood loss was 198 mL (range 75–500 mL) for LPN v 115 mL (25–300 mL) for RLPN (P = 0.169). The mean warm ischemia time was 35.3 minutes (range 15–49 min) in the LPN group and 32.1 minutes (range 30–45 minutes) in the RLPN group (P = 0.501). Conclusions: Introducing a robotic interface for laparoscopic partial/wedge resection allowed a fellowship-trained urologic oncologist with limited reconstructive laparoscopic experience to achieve results comparable to those for laparoscopic partial/wedge resection performed by experienced laparoscopic surgeons. In this regard, the learning curve appears truncated, similar to that with robot-assisted laparoscopic prostatectomy.

1 May 2006 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
EMElspeth M. McDougall
Elspeth M. McDougall
FCFederico A. Corica
Federico A. Corica
JBJohn R. Boker
John R. Boker
LSLeandro G. Sala
Leandro G. Sala
GSGabriela Stoliar
Gabriela Stoliar
RCRalph V. Clayman
Ralph V. Clayman
We present initial data on the construct, content, and face validity of the LAPMentor (Simbionix), virtual reality laparoscopic surgical simulator. Medical students (MS), residents and fellows (R/F), and experienced laparoscopic surgeons (ES), with < 30 laparoscopic cases per year (ES 30 laparoscopic cases per year (ES>30), were tested on 9 basic skill tasks (SK) including manipulation of 0-degree and 30-degree cameras (SK1, SK2), eye-hand coordination (SK3), clipping (SK4), grasping and clipping (SK5), two-handed maneuvers (SK6), cutting (SK7), fulguration (SK8), and object-translocation (SK9). Mean MS (n=23), R/F (n=24), ES30 (n=30) ages were 26 years (range 21 to 32 years), 31 years (range 27 to 39 years), 49 years (range 31 to 70 years) and 47 years (range 34 to 69 years), respectively. In the lower level skill tasks (SK3, SK4, SK5, and SK6) the ES>30, ES30 scores tended to be better than the R/F and ES30 had notably higher SK8 scores than the R/F and ES30.

7 January 2017 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
NWNicole Wake
Nicole Wake
TRTemitope Rude
Temitope Rude
SKStella K. Kang
Stella K. Kang
MSMichael D. Stifelman
Michael D. Stifelman
JBJames F. Borin
James F. Borin
HCHersh Chandarana
Hersh Chandarana

5 November 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JDJustin M Dubin
Justin M Dubin
WWWilliam Austin Wyant
William Austin Wyant
NBNavin C Balaji
Navin C Balaji
WOWilliam Lk Ong
William Lk Ong
RKReda H Kettache
Reda H Kettache
Jeremy Yuen Chun TeohJeremy Yuen Chun Teoh
Jeremy Yuen Chun Teoh
Background: Prior to the COVID-19 pandemic, urology was one of the specialties with the lowest rates of telemedicine and videoconferencing use. Common barriers to the implementation of telemedicine included a lack of technological literacy, concerns with reimbursement, and resistance to changes in the workplace. In response to the COVID-19 pandemic declared in March 2020, the delivery of urological services globally has quickly shifted to telemedicine to account for the mass clinical, procedural, and operative cancellations, inadequate personal protective equipment, and shortage of personnel. Objective: The aim of this study was to investigate current telemedicine usage by urologists, urologists’ perceptions on the necessity of in-person clinic appointments, the usability of telemedicine, and the current barriers to its implementation. Methods: We conducted a global, cross-sectional, web-based survey to investigate the use of telemedicine before and after the COVID-19 pandemic. Urologists’ perceived usability of telemedicine was assessed using a modified Delphi approach to create questions based on a modified version of the validated Telehealth Usability Questionnaire (TUQ). For the purposes of this study, telemedicine was defined as video calls only. Results: A total of 620 urologists from 58 different countries and 6 continents participated in the survey. Prior to COVID-19, 15.8% (n=98) of urologists surveyed were using telemedicine in their clinical practices; during the pandemic, that proportion increased to 46.1% (n=283). Of the urologists without telemedicine experience, interest in telemedicine usage increased from 43.7% (n=139) to 80.8% (n=257) during the COVID-19 pandemic. Among urologists that used telemedicine during the pandemic, 80.9% (n=244) were interested in continuing to use it in their practice. The three most commonly used platforms were Zoom, Doxy.me, and Epic, and the top three barriers to implementing telemedicine were patients’ lack of technological comprehension, patients’ lack of access to the required technology, and reimbursement concerns. Conclusions: This is the first study to quantify the use, usability, and pervading interest in telemedicine among urologists during the COVID-19 pandemic. In the face of this pandemic, urologists’ usage of telemedicine nearly tripled, demonstrating their ability to adopt and adapt telemedicine into their practices, but barriers involving the technology itself are still preventing many from utilizing it despite increasing interest.

1 May 2006 in Journal of Endourology
Verified
Journal Article
Closed access
JBJames F. Borin
James F. Borin
OMOri Melamud
Ori Melamud
RCRalph V. Clayman
Ralph V. Clayman
Ureteral obstruction caused by extrinsic compression by a malignancy generally can be overcome initially with a ureteral stent. However, the long-term failure rate is high, usually necessitating placement of a nephrostomy tube. Herein, we present the initial case, in this country, of intractable ureteral obstruction managed successfully with the newly developed all-metal Resonance stent (Cook Ireland Ltd., Limerick, Ireland) constructed of MP35N® alloy, a composite of nonmagnetic nickel–cobalt–chromium–molybdenum. The patient is a 64-year-old woman with metastatic breast cancer causing retroperitoneal fibrosis and ureteral obstruction diagnosed laparoscopically. The obstruction failed to respond to placement of a single 7F double-J stent and then of two 6F double-J stents in the left ureter. As a last resort, in order to avoid nephrostomy-tube placement, the 6F metal stent was placed; this provided unobstructed flow of urine, as documented on a subsequent Whitaker test and, most recently, on a renal scan, 4 months after initial stent placement.